Clean Yield Group Buys 7,266 Shares of Hologic, Inc. (NASDAQ:HOLX)

Clean Yield Group lifted its stake in Hologic, Inc. (NASDAQ:HOLX) by 18.9% in the fourth quarter, HoldingsChannel.com reports. The firm owned 45,646 shares of the medical equipment provider’s stock after purchasing an additional 7,266 shares during the quarter. Clean Yield Group’s holdings in Hologic were worth $3,291,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of HOLX. Czech National Bank lifted its position in Hologic by 6.4% in the 4th quarter. Czech National Bank now owns 50,362 shares of the medical equipment provider’s stock valued at $3,631,000 after acquiring an additional 3,046 shares in the last quarter. Fulton Bank N.A. acquired a new stake in shares of Hologic in the 4th quarter valued at about $287,000. Diversified Trust Co bought a new stake in shares of Hologic in the fourth quarter valued at about $506,000. Pensionfund Sabic raised its position in Hologic by 36.2% in the 4th quarter. Pensionfund Sabic now owns 18,800 shares of the medical equipment provider’s stock valued at $1,355,000 after buying an additional 5,000 shares during the last quarter. Finally, Nordea Investment Management AB lifted its stake in Hologic by 32.7% in the 4th quarter. Nordea Investment Management AB now owns 2,213,607 shares of the medical equipment provider’s stock valued at $159,911,000 after acquiring an additional 544,889 shares in the last quarter. Institutional investors own 94.73% of the company’s stock.

Insider Buying and Selling

In other news, COO Essex D. Mitchell sold 24,856 shares of the firm’s stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total value of $1,897,507.04. Following the sale, the chief operating officer now directly owns 27,957 shares in the company, valued at approximately $2,134,237.38. This trade represents a 47.06 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 1.75% of the stock is currently owned by company insiders.

Hologic Stock Performance

Shares of HOLX traded down $0.73 during mid-day trading on Monday, hitting $70.97. 1,991,492 shares of the company’s stock were exchanged, compared to its average volume of 1,970,938. The company has a quick ratio of 3.03, a current ratio of 3.69 and a debt-to-equity ratio of 0.49. The firm has a market cap of $16.11 billion, a price-to-earnings ratio of 21.31, a price-to-earnings-growth ratio of 2.32 and a beta of 0.97. The stock’s 50-day simple moving average is $75.88 and its 200-day simple moving average is $78.55. Hologic, Inc. has a 52 week low of $69.46 and a 52 week high of $84.67.

Hologic (NASDAQ:HOLX) last released its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.01. The firm had revenue of $987.90 million during the quarter, compared to the consensus estimate of $978.25 million. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The company’s revenue was up 4.5% compared to the same quarter last year. During the same period in the prior year, the company posted $0.89 EPS. On average, equities research analysts expect that Hologic, Inc. will post 4.28 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the stock. Morgan Stanley lowered their price objective on shares of Hologic from $84.00 to $82.00 and set an “equal weight” rating on the stock in a report on Monday. Citigroup downgraded Hologic from a “buy” rating to a “neutral” rating and lowered their target price for the company from $95.00 to $85.00 in a research report on Tuesday, October 1st. UBS Group increased their price target on Hologic from $84.00 to $90.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. Mizuho dropped their price objective on Hologic from $90.00 to $87.00 and set an “outperform” rating on the stock in a research note on Tuesday, November 5th. Finally, Wolfe Research started coverage on Hologic in a report on Friday, December 13th. They issued a “peer perform” rating for the company. Seven analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $88.92.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.